SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-24-029227
Filing Date
2024-07-26
Accepted
2024-07-26 16:05:14
Documents
16
Period of Report
2024-07-22
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 43809
2 ex3-1.htm EX-3.1 14374
3 ex99-1.htm EX-99.1 15148
4 ex99-2.htm EX-99.2 12910
  Complete submission text file 0001493152-24-029227.txt   276772

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE tnfa-20240722.xsd EX-101.SCH 3003
6 XBRL LABEL FILE tnfa-20240722_lab.xml EX-101.LAB 34916
7 XBRL PRESENTATION FILE tnfa-20240722_pre.xml EX-101.PRE 22781
18 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3986
Mailing Address 855 N. WOLFE STREET SUITE 601 BALTIMORE MD 21205
Business Address 855 N. WOLFE STREET SUITE 601 BALTIMORE MD 21205 856-848-8698
TNF Pharmaceuticals, Inc. (Filer) CIK: 0001321834 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36268 | Film No.: 241146798
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)